AR042120A1 - Ligandos receptores cannabinoides - Google Patents

Ligandos receptores cannabinoides

Info

Publication number
AR042120A1
AR042120A1 ARP030104314A ARP030104314A AR042120A1 AR 042120 A1 AR042120 A1 AR 042120A1 AR P030104314 A ARP030104314 A AR P030104314A AR P030104314 A ARP030104314 A AR P030104314A AR 042120 A1 AR042120 A1 AR 042120A1
Authority
AR
Argentina
Prior art keywords
substituted
unsubstituted
group
cycloalkyl
alkyl
Prior art date
Application number
ARP030104314A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR042120A1 publication Critical patent/AR042120A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/41—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/46—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms
    • C07C323/49—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms to sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se reivindican un compuesto de Indano, composición farmacéutica del mismo, método para preparar dicha composición y uso del mismo en tratamiento de cáncer, enfermedades inflamatorias, enfermedades Inmunomoduladoras o Enfermedades Respiratorias. Reivindicación 1: Un compuesto representado por la fórmula estructural (1), o una sal o solvato del mismo farmacéuticamente aceptable, en la cual: R1 está seleccionado del grupo que consiste en hidrógeno, alquilo sustituido o no sustituido, CF3, alcoxi sustituido o no sustituido, -N(R3)2, cicloalquilo sustituido o no sustituido, heterocicloalquilo sustituido o no sustituido, arilo sustituido o no sustituido y heteroarilo sustituido o no sustituido, donde el término "sustituido" significa que está sustituido con sustituyente(s) (X)t; R2 esta seleccionado del grupo que consiste en hidrógeno, alquilo sustituido o no sustituido, -CF3, alcoxi sustituido o no sustituido, -N(R3)2, cicloalquilo sustituido o no sustituido, heterocicloalquilo sustituido o no sustituido, arilo sustituido o no sustituido y heteroarilo sustituido o no sustituido, donde el término "sustituido" significa que está sustituido con sustituyente(s) (X)t; o R1, R2, tomados conjuntamente con Z, N e Y forman una porción heterocicloalquilo de 4-8 miembros sustituida o no sustituida, donde el término "sustituida" significa que está sustituida con sustituyente(s) (X)t; cada R3, que puede ser igual o diferente, está independientemente seleccionado del grupo que consiste en hidrógeno, alquilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, heterocicloalquilo sustituido o no sustituido, arilo sustituido o no sustituido, arilalquilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, y heteroarilalquilo sustituido o no sustituido, donde el término "sustituido" significa que está sustituido con sustituyente(s) (X)t; cada X, cuando está presente, está independientemente seleccionada del grupo que consiste en alquilo, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, arilo, heteroarilo, aminoalquilo-, -NR4R5, halo, -CF3, -OCF2H, -OCF3, -OR6, -C(O)R6, -C(O)OR6, -NR6C(O)R7, -NR6C(O)OR7, -C(O)NR4R5, -NO2, -CN, -S(O)2R6, -S(O)2NR4R5 y -NR4S(O)R5; R4 y R5, que pueden ser iguales o diferentes, están cada uno independientemente seleccionados del grupo que consiste en H o alquilo; o R4 y R5, tomados conjuntamente con N al cual están cada uno unidos, forman una porción heterocicloalquilo de 4 a 8 miembros que tiene opcionalmente un heteroátomo adicional seleccionado del grupo que consiste en N, O y S, donde el heteroátomo N adicional, cuando está presente, o cualquier átomo de carbono del anillo de la porción heterocicloalquilo pueden estar sustituidos con H o alquilo; R6 y R7, que pueden ser iguales o diferentes, están cada uno independientemente seleccionados del grupo que consiste en H o alquilo; L1 está seleccionado del grupo que consiste en -C(R2)2-, -OC(O)-, -C(O)-, -C(O)O-, -(CH(OR2))-, -S(O)2-, -S(O)-, -S-, -O-, -N(R2)-, -C(O)NH-, -NHC(O)-, -CF2- y -C(=N-OR2)-; L2 está seleccionado del grupo que consiste en un enlace covalente, -C(R2)2-, -C(=N-OR2)-, -S(O)2-, -S(O)-, -S-, -C(O)-, -O-, -N(R2), -C(O)NH-, -NHC(O)-, -OC(O)-, -C(O)O-, -(CH(OR2))- y -CF2-; M1 es una porción arilo, heteroarilo, cicloalquilo o heterocicloalquilo, donde dicha porción arilo, heteroarilo, cicloalquilo o heterocicloalquilo está sustituida con D cuando p es >= 1; M2 es una porción alquilo, cicloalquilo, heterocicloalquilo, arilo o heteroarilo, donde dicha porción alquilo, cicloalquilo heterocicloalquilo, arilo o heteroarilo, está sustituida con A cuando q es >= 1; m es 1-3; n es 0-3 donde cuando >1, cada X puede ser igual o diferente y está independientemente seleccionada; p es 0-4; q es 0-5; t es 0-6 donde cuando t > 1, cada X puede ser igual o diferente y está independientemente seleccionada; v es 1-3; A es un sustituyente opcional en M2, y cada A está independientemente seleccionada del grupo que consiste en -Br, -Cl, -F, -CF3, -OH, -OCF2H, -OCF3, alcoxi, alquilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, cicloalquilo -O-sustituido o no sustituido, heterocicloalquilo sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, -CN, -NO2, -C(O)OR4, -C(O)NR4R5, -NR4C(O)R5, -NR4R5, y -S(O)2R2, donde el término "sustituido" significa que está sustituido con (X)t y donde cuando q > 1, cada A puede ser igual o diferente; D es un sustituyente opcional en M1, y cada D está independientemente seleccionado del grupo que consiste en -Br, -Cl, -F, -CF3, -OH, -OCF2H, -OCF3, alcoxi, alquilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, cicloalquilo -O-sustituido o no sustituido, heterocicloalquilo sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, -CN, -NO2, -C(O)OR4, -C(O)NR4R5, -NR4C(O)R5, -NR4R5, y -S(O)2R2, donde el término "sustituido" significa que está sustituido con (X)n y donde cuando p > 1, cada D puede ser igual o diferente; Y está seleccionado del grupo que consiste en un enlace covalente, -(CR6R7)m-, -S(O)2-, y -C(O)-; y Z está seleccionado del grupo que consiste en un enlace covalente, -(CR6R7)v-, -S(O)0-2-, y -C(O)-, con las siguientes condiciones: cuando L2 es un enlace covalente, M2 está directamente ligado a M1; cuando Y es un enlace covalente, R1 está directamente ligado al átomo de nitrógeno de -N-Z-R2; y cuando Z es un enlace covalente, R2 está directamente ligado al átomo de nitrógeno de -N-Y-R1.
ARP030104314A 2002-11-25 2003-11-21 Ligandos receptores cannabinoides AR042120A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42886102P 2002-11-25 2002-11-25

Publications (1)

Publication Number Publication Date
AR042120A1 true AR042120A1 (es) 2005-06-08

Family

ID=32393468

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104314A AR042120A1 (es) 2002-11-25 2003-11-21 Ligandos receptores cannabinoides

Country Status (14)

Country Link
US (1) US7253189B2 (es)
EP (1) EP1565431B1 (es)
JP (2) JP4455339B2 (es)
CN (1) CN100349862C (es)
AR (1) AR042120A1 (es)
AT (1) ATE433956T1 (es)
AU (1) AU2003294449A1 (es)
CA (1) CA2506895A1 (es)
DE (1) DE60328033D1 (es)
ES (1) ES2327515T3 (es)
HK (1) HK1074040A1 (es)
MX (1) MXPA05005512A (es)
TW (1) TW200413297A (es)
WO (1) WO2004048322A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897220B2 (en) * 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
US7868204B2 (en) * 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
MXPA04002397A (es) * 2001-09-14 2004-12-02 Methylgene Inc Inhibidores de histona deacetilasa.
KR101153335B1 (ko) * 2003-09-24 2012-07-05 메틸진 인코포레이티드 히스톤 데아세틸라제의 억제제
US7253204B2 (en) * 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
AU2005307006B2 (en) * 2004-10-29 2012-05-03 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as modulators of PPAR
EP2007720B1 (en) * 2006-04-07 2013-12-25 MethylGene Inc. Benzamide derivatives as inhibitors of histone deacetylase
TW201012803A (en) * 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
CN103265480B (zh) * 2013-05-11 2015-10-07 浙江大学 喹啉二酮类衍生物及其制备方法和用途
US9636298B2 (en) 2014-01-17 2017-05-02 Methylgene Inc. Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs
TWI642658B (zh) 2017-11-01 2018-12-01 國立臺灣師範大學 茚並異喹啉衍生物的製備方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338753A (en) 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics
FR2714057B1 (fr) 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
IT1271266B (it) 1994-12-14 1997-05-27 Valle Francesco Della Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi
US5532237A (en) 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
FR2735774B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
FR2742148B1 (fr) 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
CA2245586A1 (en) 1996-02-06 1997-08-14 Japan Tobacco Inc. Novel compounds and pharmaceutical use thereof
KR20000022380A (ko) * 1996-07-01 2000-04-25 둘락 노먼 씨. 무스카린 길항제
EP0979228A4 (en) 1997-03-18 2000-05-03 Smithkline Beecham Corp CANNABINOID RECEPTOR AGONISTS
US7507767B2 (en) * 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
US7067539B2 (en) 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
NZ532291A (en) 2001-11-14 2005-11-25 Schering Corp Cannabinoid receptor ligands

Also Published As

Publication number Publication date
CA2506895A1 (en) 2004-06-10
HK1074040A1 (en) 2005-10-28
US7253189B2 (en) 2007-08-07
MXPA05005512A (es) 2005-07-25
WO2004048322A1 (en) 2004-06-10
EP1565431B1 (en) 2009-06-17
CN1741992A (zh) 2006-03-01
JP2010059169A (ja) 2010-03-18
DE60328033D1 (de) 2009-07-30
JP2006507347A (ja) 2006-03-02
AU2003294449A1 (en) 2004-06-18
EP1565431A1 (en) 2005-08-24
US20040132804A1 (en) 2004-07-08
JP4455339B2 (ja) 2010-04-21
ES2327515T3 (es) 2009-10-30
TW200413297A (en) 2004-08-01
ATE433956T1 (de) 2009-07-15
CN100349862C (zh) 2007-11-21

Similar Documents

Publication Publication Date Title
AR042120A1 (es) Ligandos receptores cannabinoides
LTPA2020531I1 (lt) Pleuromutilino dariniai, skirti mikrobų sukeltų ligų gydymui
IT1251376B (it) Pregna 1,4-diene-3,20-dione-16,17-acetal-21-esteri, procedimento per la loro preparazione, composizione e metodi per il trattamento di stati infiammatori
NO20052167L (no) Hjelpemidler eller preventivmidler mot urineringsfrekvens eller urinkontinens og morfinanderivater med nitrogenholdig heterocyklisk gruppe
MX9206114A (es) Derivados de urea y proceso para su preparacion
CO5580765A2 (es) Derivados de ciclohexano espirociclicos
HK1167658A1 (en) Composition for the preparation of 17-vinyl- triflates as intermediates 17--
CO6160266A2 (es) Derivado de oxopirazina y herbicida
BR0116539A (pt) Derivados de piridona tendo uma atividade de ligação para o receptor 2 do tipo canabinóide
ATE489050T1 (de) Photochemische gewebeverbindung
AR052682A1 (es) DERIVADOS DE 5, 6, 7, 8 - TETRAHIDROTIEN[2, 3 - B]QUINOLINA uTILES PARA INHIBIR LA ACTIVIDAD DE QUINESINA DE KSP, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS.
PE20060765A1 (es) Analogos de rapamicina
ES2072939T3 (es) Nuevos derivados de esteroides.
AR037826A1 (es) Derivados de piridazina fusionada
FI903917A0 (fi) Foerfarande foer framstaellning av med metallradionuklider maerkta proteiner.
NO901494D0 (no) Fremgangsmaate for fremstilling av interfenylen-7-oksabicykloheptyl-substituerte heterocykliske amid-prostaglandinanaloger.
NO984195D0 (no) Nye benzofuranonderivater og fremgangsmåte for fremstilling derav
NO984532L (no) Nye tetralon- eller benzopyranonderivater og fremgangsmÕte for fremstilling derav
ES2068881T3 (es) Procedimiento para preparar complejos metalicos con grupo funcional isotiocianato.
AR038118A1 (es) Compuestos derivados de la bencinamida del acido 7-oxo-4,7-dihidrotien[2,3-b[piridin-6-carboxilico 3-sustituido que son utiles como antivirales
ATE215555T1 (de) 17-beta.-allyloxy(thio)alkyl-androstan derivative zur modulation von meiose
AR036533A1 (es) Compuestos agonistas de retinoides de alquil urea, su utilizacion, composiciones farmaceuticas que los comprenden y medicamentos basados en dichos compuestos
ES431497A1 (es) Procedimiento para preparar un derivado de s-triazol (1,5- a) piridina.
FI925833A (fi) Tricykliskt triazolderivat, dess framstaellning och dess anvaendning
EP0277688A3 (en) Method for preparing thiol compounds

Legal Events

Date Code Title Description
FB Suspension of granting procedure